Two-dimensional burst identification codes and their use in burst correction

A new class of codes, called burst identification codes, is defined and studied. These codes can be used to determine the patterns of burst errors. Two-dimensional burst correcting codes can be easily constructed from burst identification codes. The resulting class of codes is simple to implement and has lower redundancy than other comparable codes. The results are pertinent to the study of radiation effects on VLSI RAM chips, which can cause two-dimensional bursts of errors

On the existence of optimum cyclic burst-correcting codes

It is shown that for each integer b >= 1 infinitely many optimum cyclic b-burst-correcting codes exist, i.e., codes whose length n, redundancy r, and burst-correcting capability b, satisfy n = 2^{r-b+1} - 1. Some optimum codes for b = 3, 4, and 5 are also studied in detail

Computational Analysis of Ares I Roll Control System Jet Interaction Effects on Rolling Moment

The computational flow solver USM3D was used to investigate the jet interaction effects from the roll control system on the rolling moment of the Ares I full protuberance configuration at wind tunnel Reynolds numbers. Solutions were computed at freestream Mach numbers from M = 0.5 to M = 5 at the angle of attack 0deg, at the angle of attack 3.5deg for a roll angle of 120deg, and at the angle of attack 7deg for roll angles of 120deg and 210deg. Results indicate that the RoCS housing provided a beneficial jet interaction effect on vehicle rolling moment for M > or = 0.9. Most of the components downstream of the roll control system housing contributed to jet interaction penalties on vehicle rolling moment

IoTility:Architectural Requirements for Enabling Health IoT Ecosystems

The increasing ubiquity of the Internet of Things (IoT) has the potential to drastically alter the way healthcare systems are utilized at home or in a care environment. Smart things offer new ways to assist in general patient wellness, such as promoting an active and healthy lifestyle and simplifying treatment management. We believe smart health things bring new requirements not typically addressed in traditional IoT systems, and that an architecture targeting these devices must address such requirements to fully utilize their potential and safe usage. We believe such an architecture will help improve adoption and efficacy, closing gaps between the variety of emerging health IoT systems. In this paper, we present a number of requirements we consider integral to the continued expansion of the digital health IoT ecosystem (Health IoT). We consider the current landscape of IoT in relation to these requirements and present solutions that address two pressing requirements: 1) democratizing mobile health apps (giving users control and ownership over their app and data), and 2) making mobile apps act and behave like any other thing in an IoT. We present an implementation and evaluation of these Health IoT requirements to show how health-specific solutions can drive and influence the design of more generalized IoT architectures

Nε-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status

In comparison to the general population, individuals with diabetes suffer a 3- to 4-fold increased risk for developing complications of atherosclerosis and vascular insufficiency. This fact should be taken into account to develop a suitable determinant for the early detection of these complications and subsequently reduce the adverse effect of type 2 diabetes. In vitro experiments have shown that the products of glucose auto-oxidation and Amadori adducts are both potential sources of Nε-(carboxymethyl)lysine (CML). Excessive formation of CML on low density lipoprotein (LDL) has been proposed to be an important mechanism for the dyslipidemia and accelerated atherogenesis observed in patients with type 2 diabetes. It has been postulated that the uptake of CML-LDL by LDL receptors is impaired, thereby decreasing its clearance from the blood circulation. Alternatively, the uptake of these modified LDL particles by scavenger receptors on macrophages and vascular smooth muscle cells (SMCs) and by AGE receptors on endothelial cells, SMCs, and monocytes is highly enhanced and this, in turn, is centrally positioned to contribute to the pathogenesis of diabetic vascular complications especially coronary artery disease. The present review summarizes the up-to-date information on effects and mechanism of type 2 diabetes-associated coronary atherosclerosis induced by CML-LDL modification

A 3D printed drug delivery implant formed from a dynamic supramolecular polyurethane formulation

Using a novel molecular design approach, we have prepared a thermo-responsive supramolecular polyurethane as a matrix material for use in drug eluting implants. The dynamic supramolecular polyurethane (SPU) is able to self-assemble through hydrogen bonding and π-π stacking interactions, resulting in an addressable polymer network with a relatively low processing temperature. The mechanical properties of the SPU demonstrated the material was self-supporting, stiff, yet flexible thus making it suitable for hot-melt extrusion processing, inclusive of related 3D printing approaches. Cell-based toxicity assays revealed the SPU to be non-toxic and therefore a viable candidate as a biocompatible polymer for implant applications. To this end, the SPU was formulated with paracetamol (16 %w/w) and 4 wt% or 8 wt% poly(ethylene glycol) (PEG) as an excipient and hot melt extruded at 100 °C to afford a 3D printed prototype implant to explore the extended drug release required for an implant and the potential manipulation of the release profile. Furthermore, rheological, infra-red spectroscopy, powder X-ray diffraction and scanning electron microscopy studies revealed the chemical and physical properties and compatibility of the formulation components. Successful release of paracetamol was achieved from in vitro dissolution studies and it was predicted that the drug would be released over a period of up to 8.5 months with hydrophilic PEG being able to influence the release rate. This extended release time is consistent with applications of this novel dynamic polymer as a drug eluting implant matrix

Role of Nε-(Carboxymethyl)Lysine in the Development of Ischemic Heart Disease in Type 2 Diabetes Mellitus

This study aims to determine the levels of Nε-(carboxymethyl)lysine (CML) in patients with Type 2 diabetic patients with and without ischemic heart disease (IHD) and to find for a possible association between circulating CML and a number of clinical parameters including lipids, hemoglobin A1c (HbA1c) and malondialdehyde (MDA) in Type 2 diabetic IHD patients. Serum CML levels were measured by enzyme-linked immunosorbent assay using polyclonal anti-CML antibodies. Serum levels of CML and MDA were assessed in 60 IHD patients with Type 2 diabetes, 43 IHD patients without Type 2 diabetes, 64 Type 2 diabetics without IHD, and 80 sex- and age-matched healthy subjects. Correlations studies between CML levels and lipids, HbA1c, and lipid peroxidation were performed in Type 2 diabetes patients with and without IHD. A statistical significance was observed in the levels of serum glucose, lipids (triglyceride, total cholesterol, HDL-cholesterol), MDA, HbA1c, CML and LDL-cholesterol (p<0.05) between the groups of the study. CML levels were significantly increased in diabetic IHD patients compared with Type 2 diabetes patients but without IHD (537.1 ± 86.1 vs 449.7 ± 54.9, p<0.001). A positive correlation was observed between serum levels of CML and MDA, r = 0.338 (p = 0.008) in Type 2 diabetes patients with IHD. However, age, HbA1c and lipids had no significant influence on CML levels among diabetics (p>0.05). In conclusion, this study demonstrates the effect of both diabetes and oxidative stress on the higher levels of circulating CML. These results showed that increased serum levels of CML are associated with the development of IHD in Type 2 diabetes mellitus